Our research is centered on the function of nuclear oncogenes and their role in cancer development (recently published studies: Bhandare et al, Nucleic Acids Research, 2025; Vogt et al, Gut, 2024; Solvie et al, Nature 2022; Narain et al, Molecular Cell). A major focus is the development of PROTAC molecules as novel pharmaceutical strategies against cancer. Further information about our work can be found at: www.uni-kiel.de/Biochemie/wolf The successful candidates will work in an ERC (i.e. European Research Council consolidator grant “PROTAC-PDAC”) or German Cancer Aid funded project. The research group is located at the Institute of Biochemistry, which is part of the Medical Faculty of the University of Kiel. The institute provides excellent equipment allowing state-of-the-art experiments and the candidate will learn techniques, which are highly beneficial for their later carrier in academia or industry. The department is located at the Campus of the University of Kiel, which provides a stimulating collaborative research environment with multiple research groups working on tumor biology and cellular proteolysis. We collaborate with many additional life science institutes in Kiel including the Kiel Oncology Network (KON), the Institute of Pharmacy and Kiel Life Science (KLS). Applicants should have a Master's degree in a life science discipline and a strong background in biochemistry, molecular biology, cell biology or bioinformatics. Good knowledge of English is required. We are looking for excellent PhD students to join the Tumor Biochemistry group of Elmar Wolf. The positions will start between August and Dezember 2025 and the salary is based on TV-L E 13 (65%). In case of equivalent qualifications, disabled applicants will be preferentially considered.